Quantitative Investment Management LLC Takes Position in IQVIA Holdings Inc. $IQV

Quantitative Investment Management LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,754 shares of the medical research company’s stock, valued at approximately $2,422,000.

A number of other large investors also recently added to or reduced their stakes in the business. Physician Wealth Advisors Inc. grew its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the period. Atlantic Union Bankshares Corp bought a new position in IQVIA in the third quarter valued at approximately $36,000. Asset Dedication LLC grew its holdings in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the period. Finally, Rothschild Investment LLC grew its holdings in IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 5.3%

IQVIA stock opened at $162.45 on Friday. The company has a 50 day moving average of $202.79 and a 200-day moving average of $206.83. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The stock has a market capitalization of $27.57 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 1.66 and a beta of 1.39.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on IQV shares. Truist Financial cut their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Mizuho set a $215.00 price objective on IQVIA in a report on Monday, February 23rd. Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Jefferies Financial Group lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Buy” and a consensus price target of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.